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A B S T R A C T
Cystic ﬁbrosis (CF) infections are invariably bioﬁlm-mediated and polymicrobial, being safe to assume that a
myriad of factors aﬀects the sociomicrobiology within the CF infection site and modulate the CF community
dynamics, by shaping their social activities, overall functions, virulence, ultimately aﬀecting disease outcome.
This work aimed to assess changes in the dynamics (particularly on the microbial composition) of dual-/three-
species bioﬁlms involving CF-classical (Pseudomonas aeruginosa) and unusual species (Inquilinus limosus and
Dolosigranulum pigrum), according to variable oxygen conditions and antibiotic exposure.
Low ﬂuctuations in bioﬁlm compositions were observed across distinct oxygen environments, with dual-
species bioﬁlms exhibiting similar relative proportions and P. aeruginosa and/or D. pigrum populations dom-
inating three-species consortia. Once exposed to antibiotics, bioﬁlms displayed high resistance proﬁles, and
microbial compositions, distributions, and microbial interactions signiﬁcantly challenged. The antibiotic/oxygen
environment supported such ﬂuctuations, which enhanced for three-species communities.
In conclusion, antibiotic therapy hugely disturbed CF communities’ dynamics, inducing signiﬁcant compo-
sitional changes on multispecies consortia. Clearly, multiple perturbations may disturb this dynamic, giving rise
to various microbiological scenarios in vivo, and aﬀecting disease phenotype. Therefore, an appreciation of the
ecological/evolutionary nature within CF communities will be useful for the optimal use of current therapies and
for newer breakthroughs on CF antibiotherapy.
1. Introduction
According to the World Health Organization, infectious respiratory
diseases are a major cause of morbidity and mortality worldwide, ac-
counting for 4.18 million premature deaths per year (WHO, 2013). It is
believed that most – if not all – of these infections are associated with
bioﬁlms, which represent a critical health-care burden (Bjarnsholt
et al., 2013) because of their great contribution to the emergence and
dissemination of antibiotic resistance. Cystic ﬁbrosis (CF) is a common
heritable genetic disorder (100 000 people estimated to be aﬀected)
(Davies et al., 2014) with major debilitation in the respiratory tract,
where patients are prone to develop severe bioﬁlm-related infections.
CF infection was originally characterized as monomicrobial, likely due
to the extensive use of culture-dependent isolation techniques. How-
ever, the advent of aﬀordable high-resolution molecular technologies
has dramatically changed our view on the true diversity of microbes
present in the CF airways (Lopes et al., 2015). Indeed, the large variety
and concentration of microbes includes not only the key pathogens
habitually recovered (e.g. Pseudomonas aeruginosa) but also unusual
species (e.g. Inquilinus limosus, Stenotrophomonas maltophilia, Dolosi-
granulum pigrum, Pneumoncystis jirovecii, Scedosporium spp., adenovirus,
rhinovirus, etc.) (Bittar et al., 2008; Coenye et al., 2002; Pederiva et al.,
2012). Though that CF aetiology is invariably polymicrobial, most re-
search has focused on speciﬁc pathogens, failing to consider the role of
unusual microbes in the disease progression (Lopes et al., 2014; , 2015;
Magalhães et al., 2016; Waters, 2012) or their social interactions with
established pathogens (Lopes et al., 2012). Accordingly, I. limosus (a
gram-negative aerobe with a very mucoid phenotype) (Coenye et al.,
2002) and D. pigrum (a gram-positive, facultative anaerobe, arranged in
pairs, tetrads, and clusters) (Aguirre et al., 1993) are less typical bac-
teria reported in expectorated CF patients (Bittar et al., 2008). Whilst
the pathogenic potential of I. limosus has been already pointed (Chiron
et al., 2005), information on D. pigrum is still limited and its role in CF
infection unclear. The upper respiratory tract is thought to be its natural
habitat (Laclaire and Facklam, 2000), but its occurrence in other
polymicrobial contexts (Hoedemaekers et al., 2006; Lecuyer et al.,
2007) has raise up interest in evaluating its pathogenic potential in CF
polymicrobial communities. Interestingly, earlier in vitro studies have
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unravelling the contribute of I. limosus and D. pigrum for the resilience
of CF-associated bioﬁlms to antibiotic treatment (Lopes et al., 2014;
Lopes et al., 2012), thereby allowing to hypothesize their inﬂuence in
the behaviour of coexisting species or even in beneﬁting the whole
community. It is likely that the multifaceted CF microbiome promotes
for species-speciﬁc relationships, often necessary for the development
and structure of the community and other regulatory activities that
coordinate the whole community (Magalhães et al., 2016; Tolker-
Nielsen and Molin, 2000). In addition, it is now evident that microbial
communities can be modulated by a wide variety of other factors that,
altogether, give rise to various microbiological scenarios seen in vivo
and are likely to aﬀect disease phenotype and the clinical outcome
(Guss et al., 2011; Magalhães et al., 2016; Peters et al., 2012a;
Stressmann et al., 2011), as has been determined for other pathologies
(Azevedo et al., 2014; Azevedo et al., 2016; LiPuma, 2014; Peters et al.,
2012b). For instance, the physicochemical characteristics of the air-
ways; the administration of the antibiotic therapy, (maintenance vs.
treatment of episodes of acute exacerbation); the nature of the pre-ex-
isting microbial community; the concomitant airway inﬂammation re-
sulting from chronic infections as well as patient- and/or disease-as-
sociated issues (increasing age, disease progression, reduced lung
function) have been suggested to have a crucial impact on the dynamics
of CF polymicrobial communities (Cuthbertson et al., 2016; Klepac-
Ceraj et al., 2010; Rogers et al., 2015; Serisier, 2013; van der Gast et al.,
2014; Willner et al., 2012; Zhao et al., 2012). Altogether, these factors
may drive to social, structural and functional diversiﬁcation and con-
sequently impact the ecology and evolution in natural species popula-
tions (Allen and Banﬁeld, 2005; Schloter et al., 2000). Although it is
still almost impossible to predict bioﬁlm behavior and the dynamics of
a community, it is now increasingly recognized that its regulatory
networks (e.g. social activities, overall functions, virulence traits, etc.)
are often strictly evolved in response to those highly variable stimuli
(Allen and Banﬁeld, 2005; Nadell et al., 2016), and improving and di-
recting eﬀorts to better understand how polymicrobial infections be-
have and respond to surrounding stresses may give insights to better
predict disease progression and to deﬁne more eﬀective antimicrobial
strategies.
In this scope, this study aimed at deeply investigating the behavior
of I. limosus and D. pigrum when associated with the CF-conventional
pathogen P. aeruginosa in dual-species and even in three-species po-
pulations. The response of these multispecies communities to aerobic
(AER) microaerophilic (MAER) and anaerobic (ANAER) conditions re-
sembling the CF airways and to subsequent antibiotic interventions was
further examined in detail. Thus, changes in the bioﬁlm-formation
ability, antibiotic resistance proﬁles, bacterial killings, microbial com-
position and distribution within the multispecies bioﬁlms were as-
sessed.
2. Material and methods
2.1. Bacterial strains and culture conditions
The bacterial strains used in this work were: P. aeruginosa (strain
UCBPP- PA14), I. limosus (strain M53, isolated from CF sputum), and D.
pigrum (CIP 104051T, purchased from Institute Pasteur Collection,
Paris, France). All strains were stored at−70 °C in 20% (v/v) glycerol.
Prior to inoculation, bacteria were subcultured twice from the frozen
stock preparations onto tryptic soy broth (TSB, Lioﬁlchem, Italy) sup-
plemented with 1.2% (w/v) agar (TSA, Lioﬁlchem) plates and in-
cubated at 37 °C for 24–48 h.
2.2. Formation of multispecies bioﬁlms under variable oxygen conditions
The formation of dual- and three-species bioﬁlms formed by P.
aeruginosa, I. limosus and D. pigrum under AER, MAER and ANAER
conditions was performed as described elsewhere (Lopes et al., 2014).
Brieﬂy, for preparing bioﬁlm inocula, several colonies from a fresh
subculture of each strain were suspended in TSB to match a 1.0
McFarland standard. This was further diluted in broth medium (TSB) to
obtain pure cultures with∼107 cells/mL. For dual-species cultures, the
suspended inoculum of each species was combined in a 1:1 ratio,
whereas the three-species cultures were obtained by mixing the three
pure bacterial suspensions in equal proportions. Bacterial suspensions
were dispensed in standard 96-well microtiter plate wells and incubated
at 37 °C and 120 rpm until achieving the threshold the cell concentra-
tion interval of 2 × 105 to 2 × 106 CFU/cm2 (determined by previous
established bioﬁlm growth curves) (Lopes et al., 2014). To resemble the
oxygen environments of CF airways, plates were incubated at diﬀerent
conditions: AER (n-biotek, Model NB-205Q, Korea incubator), MAER
(Thermo Scientiﬁc, Forma 311, USA incubator, calibrated with 5% v/v
CO2) and ANAER (AnaeroGen Atmosphere Generation system, Oxoid,
Cambridge, UK). The ANAER atmosphere was created by sealing the
plates containing the cells suspensions in plastic boxes with AnaeroGen
sachets (Oxoid), which reduces oxygen concentration to below 1% (v/
v). This oxygen reduction was conﬁrmed by using anaerobic indicator
strips (Oxoid) (see Fig. S1 in Supplementary Material).
2.3. Quantiﬁcation of biomass and metabolic activity of bioﬁlms
After bioﬁlm formation, the content of microtiter plate wells
(planktonic cell fraction) was discarded, the wells washed once with
sterile 0.9% (w/v) saline solution to remove non-adherent and weakly
adherent bacteria, and bioﬁlms were quantiﬁed for biomass and me-
tabolic activity. Bioﬁlm mass quantiﬁcation was based on staining
bioﬁlms with crystal violet (CV), with protocol adapted from
Stepanovic et al. (Stepanovic et al., 2000). Brieﬂy, the wells were air
dried for 10 min before ﬁxing attached bacteria with pure methanol
(Fisher Scientiﬁc, Leicestershire, UK) for 15 min. Then, bioﬁlms were
stained for 1 min with 1% (v/v) CV (Merck, Germany). The excess stain
was removed by washing twice the wells with sterile distilled water.
Lastly, the bound dye was dissolved in pure methanol (200 μL/well)
and the optical density (OD) was read at 550 nm (OD550nm) in a mi-
crotiter plate reader (Model Sunrise-basic Tecan, Austria).
The metabolic activity of bioﬁlms was measured using the 2,3-bis
(2-methoxy-4-nitro-5-sulfophenyl)-2Htetrazolium-5-carboxanilide so-
dium salt (XTT) colorimetric method, initially described by Stevens and
Olsen (Stevens and Olsen, 1993), with some modiﬁcations. Basically,
after bioﬁlm growth and washing procedures, 200 μL of a combined
solution of XTT (Sigma) and phenazine methosulfate (PMS) (Sigma)
were added to each well in order to obtain a ﬁnal concentration of
150 mg/L of XTT and 10 mg/L of PMS. After that, plates were in-
cubated at 37 °C for 3 h in the dark. Bioﬁlm metabolic activity was
determined by reading the OD at 490 nm (OD490nm) in each well.
2.4. Determination of the competitive index (CI) and the relative increase
ratio (RIR)
In order to determine whether the species could compete with each
other in multispecies bioﬁlms, the Competitive Index (CI) was deﬁned
as the X/Y ratio within the output sample (immediately after bioﬁlm
formation) divided by the corresponding ratio in the inoculum (input):
CI [X vs Y] = [N (X/Y)output/N (X/Y)input]
where N is the value of CFU/cm2 obtained for the species X or Y in
the bioﬁlm, in the output (at ﬁxed times) and input (t = 0 or the in-
oculum) sample (Macho et al., 2007). For statistical analyses, CI values
were ﬁrst subjected to a Log transformation for normal distribution,
then interpreted as follows: a CI value equal to 0 indicates equal
competition of species X and Y in the consortium; a positive CI value
indicates a competitive advantage for the species X; a negative CI value
indicates a competitive advantage for the species Y. Similarly, the
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Relative Increase Ratio (RIR) was calculated and based on the growth
results obtained from the single-species bioﬁlms formed by each strain.
Calculations were adapted from (Macho et al., 2007). Statistical sig-
niﬁcant diﬀerences between CI and RIR means for each case were
suggestive of a meaningful competition between the species in the
consortia.
2.5. Bioﬁlm resistance proﬁles
Antibiotics susceptibilities of bioﬁlms were determined by adapting
the protocol described by Ceri et al. (Ceri et al., 1999). For that, pre-
established bioﬁlms (containing 2 × 105 to 2 × 106 CFU/cm2) formed
on the microtiter plate wells were exposed to increasing 2-fold con-
centrations (ranging from 2 to 1024 mg/L) of 9 clinically-relevant an-
tibiotics: tobramycin (TOB), gentamicin (GEN), levoﬂoxacin (LVF), ci-
proﬂoxacin (CIP), clindamycin (CLI), cefotaxime (CTX),
chloramphenicol (CAM), rifampicin (RIF) and aztreonam (ATM, all
from Sigma), prepared in cation-adjusted Mueller-Hinton broth (C-
AMHB). Plates were then incubated at 37 °C, under AER, MAER and
ANAER environments, as described above. Following 24 h of antibiotic
exposure, planktonic cell fractions (supernatant) released for treated-
bioﬁlms were transferred to new microtiter plates and the minimum
inhibitory concentrations (MICs) were obtained by reading the OD at
650 nm (OD650 nm), where OD650 nm < 0.1 was evidence of bacterial
growth inhibition. Bioﬁlms attached to the wells were rinsed twice with
saline solution and disrupted (by sonication with an ultrasound bath)
into TSB supplemented with 1% (v/v) tween® 20 (Fisher Scientiﬁc, NJ,
USA). The minimum bioﬁlm eradication concentration (MBEC), corre-
sponding to the lowest antibiotic concentration able to inhibit bioﬁlm
growth, was determined after plating serial dilutions of disrupted bio-
ﬁlms samples onto TSA.
2.6. Assessment of bacterial killings within bioﬁlms after antibiotic exposure
The eﬃcacy of the aforementioned antibiotics at concentrations
equal to 2, 128 and 1024 mg/L was evaluated for bacterial killings
within bioﬁlms, which was expressed in terms of percentage reduction
in bioﬁlm-cell numbers. After bioﬁlms being exposed to antibiotics (as
previously described), total cultivable cell numbers were enumerated
by plating 10-fold serially diluted bioﬁlm-detached samples onto TSA
plates. Bioﬁlm-cell killing was reported as the percentage of log re-
duction calculated to the relative cell count at the time of initiation of
antibiotic exposure, according to the following:
Bioﬁlm-cell reduction (%) = 100− [N (after exposure to the anti-
biotic)/N (prior to antibiotic exposure) × 100]
where N is the value of CFU/cm2 present in the bioﬁlm determined
before or after being exposed to the antibiotic at the desired con-
centration.
2.7. Determination of bioﬁlms composition
In this work, the relative species composition within polymicrobial
bioﬁlms was estimated before and after antibiotic exposure. Basically,
after the bioﬁlms rinse step, the wells were ﬁlled with saline solution
(200 μL/well) and bioﬁlms formed in the wells were detached by so-
nication using an ultrasound bath (Sonicor, model SC-52, UK) operating
at 50 kHz, during 10 min and then resuspended by pipetting up and
down. The sonication step was previously optimized to ensure that all
cells were detached from the wells of the microtiter plate, while
avoiding cell disruption (data not shown). The estimation of total bio-
ﬁlms-cells was enumerated by using TSA whereas selective agar media
was used to discriminate each bacterial population in the consortia:
Pseudomonas isolation agar (PIA; Sigma) and Burkholderia cepacia se-
lective agar, (BCSA; Oxoid Ltd, Hampshire, UK) supplemented with 300
000 IU/L polymyxin B (Biochrom, Berlin, Germany) and 100 mg/L ti-
carcillin (Sigma) for P. aeruginosa and I. limosus isolation, respectively.
Due to the lack of a speciﬁc selective medium for D. pigrum, this species
was estimated by the diﬀerence between the average total cell number
(in TSA) and the average of other bacteria presented in the consortia.
2.8. Multiplex PNA FISH assay applied to bioﬁlms
In order to discriminate the diﬀerent populations within the poly-
microbial bioﬁlms and to conﬁrm (qualitatively) the results obtained
from culture, ﬂuorescence in situ hybridization (FISH) using peptide-
nucleic acid (PNA) probes followed by an additional staining step with
4‘, 6-diamidino-2-phenylindole (DAPI; Sigma) was performed directly
on polymicrobial consortia. Firstly, bioﬁlms were formed on the surface
of Nunc™ Lab-Tek™ II Chamber Slide™ System (Nalge Nunc
International; Naperville, IL, USA). After achieving the threshold con-
centration, bioﬁlms were washed twice with 1 mL of sterilized deio-
nized water and air dried at ∼60 °C for 15 min. Bioﬁlms were then
ﬁxed with methanol (100% v/v) for 20 min, followed by 4% (w/v)
paraformaldehyde and 50% (v/v) ethanol (10 min each), at room
temperature. After the ﬁxation step, the surfaces of the chamber slide
were covered with 20 μL of hybridization solution with a mixture of
two probes at 200 nM and covered with coverslips. These PNA probes,
designated Paer565 and Ilim569, were previously developed, optimized
and validated (Lopes et al., 2017) in order to speciﬁcally detect P.
aeruginosa and I. limosus within polymicrobial communities. Hy-
bridization was performed in the dark, for 1 h at 65 °C, as determined
elsewhere (Lopes et al., 2017). For washing (65 °C for 30 min), a fresh
solution composed of 5 mM Tris Base, 15 mM NaCl and 1% (v/v) Triton
X-100 (all from Sigma) was prepared less than 24 h before use. Finally,
the chamber slides were allowed to air dry in the dark. An additional
staining step with DAPI was performed at the end of the hybridization
procedure, covering the surfaces with 20 μL of DAPI (40 μg/mL) for
5 min at room temperature in the dark. Then, immediate observation
was elaborated in the ﬂuorescence microscope. Negative controls were
performed for each experiment, with no probes added to the hy-
bridization solution. For microscopic visualization, a ﬂuorescence mi-
croscope (Olympus BX51, Peraﬁta, Portugal) equipped with the ﬁlters
sensitive to DAPI (BP 365-370, FT 400, LP 421) and to the signaling
molecule of the PNA probes (BP 470–490, FT 500, LP 516 and BP
530–550, FT 570, LP 591, for Alexa 488 and 594, respectively) was
used.
2.9. Statistical analysis
Data were analyzed using the Prism software package (GraphPad
Software version 6.0 for Macintosh). Results were compared by one-
way analysis of variance (ANOVA) and applying the Tukey multi-
comparison post-test. Diﬀerences were considered statistically sig-
niﬁcant at P values< 0.05.
3. Results
3.1. Bioﬁlm mass and metabolic activity under diﬀerent oxygen conditions
In order to inspect for changes in bioﬁlm phenotype under variable
oxygen conditions, dual- and three-species bioﬁlms encompassing the
CF-associated species I. limosus, D. pigrum and P. aeruginosa were grown
under AER, MAER and ANAER environments, being further analyzed in
terms of biomass and metabolic activity (Fig. 1). An incubation period
of 6 h was required for bioﬁlms to achieve the threshold interval
(2 × 105 to 2 × 106 CFU/cm2) as was previously determined by bio-
ﬁlm adhesion kinetics under the selected oxygen conditions (Fig. S2).
Regarding bioﬁlm mass (Fig. 1a), dual-species bioﬁlms encompassing P.
aeruginosa and I. limosus produced the lowest values in comparison with
dual-species bioﬁlms of P. aeruginosa and D. pigrum and the consortia
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involving the three species. The same tendency was observed for the
metabolic activity of these bioﬁlms (Fig. 1b). Overall, bioﬁlms tend to
develop signiﬁcantly less biomass and present lower metabolic activity
for limited oxygen conditions, in particular under ANAER (P < 0.05).
A particular increase in the metabolic activity was observed for P.
aeruginosa and D. pigrum dual-species consortia developed under a
MAER environment.
3.2. Microbial composition of bioﬁlms under variable oxygen conditions
In order to investigate which bacterial species were prevailing in the
bioﬁlms under AER, MAER and ANAER conditions, the relative popu-
lation distributions were determined by culture (Fig. 2a). Previously to
antibiotic exposure, dual-species bioﬁlms generally presented similar
bacterial proportions for all oxygen environments, with P. aeruginosa
slightly dominating the overall consortia with I. limosus and occupying
similar extents with D. pigrum. Likewise, the three-species bioﬁlms were
clearly dominated by P. aeruginosa and D. pigrum, whereas I. limosus was
the smallest representative population in the overall bioﬁlm. In order to
better discriminate and to infer about changes in the distribution and
prevalence of the bacterial populations within the multispecies con-
sortia, a multiplex PNA-FISH counterstained with DAPI was employed
directly on bioﬁlms (Fig. 2b). Overall, FISH images seemed to qualita-
tively corroborate culture results. In regard to dual-species bioﬁlms,
both populations were detected, with P. aeruginosa (red cells) and D.
pigrum (blue cells) occupying similar extensions in the consortia, but
with P. aeruginosa slightly dominating the dual-species bioﬁlms en-
compassing I. limosus. Together with D. pigrum, P. aeruginosa still pre-
vailed in the three-species consortia, whereas I. limosus populations
were sparsely detected under ﬂuorescence microscopy.
3.3. Interspecies competition within bioﬁlms
For a clear understanding of the competition between the species
Fig. 1. Characterization of polymicrobial bioﬁlms
formed by P. aeruginosa (PA), I. limosus (IL) and D.
pigrum (DP) in terms of (a) biomass and (b) meta-
bolic activity. Bioﬁlms were grown in microtiter
plate wells under aerobic (AER), microaerophilic
(MAER) and anaerobic (ANAER) atmospheres until
achieving the threshold concentration of 2 × 105 to
2 × 106 CFU/cm2 (6 h). The means ± SDs for three
independent assays are presented. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001, AER
vs. MAER vs. ANAER, one-way ANOVA with Tukey‘
post-hoc test.
Fig. 2. Characterization of polymicrobial bioﬁlms formed by P. aeruginosa (PA), I. limosus (IL) and D. pigrum (DP) in terms of (a) microbial compositions and (b) location and distribution
of the populations. Bioﬁlms were grown in microtiter plate wells under aerobic (AER), microaerophilic (MAER) and anaerobic (ANAER) atmospheres until achieving the threshold
concentration of 2 × 105 to 2 × 106 CFU/cm2 (6 h). In (a), the microbial compositions were determined by culture and were expressed as the average of the relative species proportions
in the consortia; in (b) a multiplex PNA-FISH assay followed by DAPI staining was applied to the polymicrobial bioﬁlms, in order to discriminate between the populations in the consortia.
Images resulted from the bands superposition of the three channels used to visualize the ﬂuorochromes used (Alexa ﬂuor 594, red: PA; Alexa Fluor 488, green: IL; DAPI, blue: DP). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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during bioﬁlm growth under AER, MAER and ANAER environments,
the CI and RIR indexes were estimated for dual- and three-species
bioﬁlms (Fig. 3). Whilst CI allows comparing the diﬀerences among the
growth of each species in mixed cultures, the RIR index compares the
growth of species within pure cultures. As shown, a negative CI index
was observed for the P. aeruginosa/I. limosus dual-species consortia
(Fig. 3a), meaning a competitive advantage for P. aeruginosa over I.
limosus. However, this competition was only signiﬁcant for AER con-
ditions (CI vs. RIR, P < 0.01). By the contrary, for dual-species con-
sortia involving P. aeruginosa/D. pigrum, the unusual species clearly
presented competitive advantage over P. aeruginosa for all oxygen en-
vironments (CI > 0; CI vs. RIR, P < 0.0001) (Fig. 3b). Similarly,
when both unusual species were in co-culture with P. aeruginosa
(Fig. 3c), I. limosus was outcompeted by P. aeruginosa (CI < 0),
whereas D. pigrum still outcompeted the conventional CF-associated
species in the consortia for all oxygen conditions (CI > 0; CI vs. RIR,
P < 0.05). Equally, negative CI indexes indicated D. pigrum sig-
niﬁcantly dominating over I. limosus growth within the three-species
consortia under all environments (CI < 0; CI vs. RIR, P < 0.0001).
Other approach to represent these latest results consisted in calculating
the relative ﬁtness of P. aeruginosa when co-cultured with the unusual
species (Fig. S3). This demonstrated enhanced P. aeruginosa ﬁtness
when co-cultured with I. limosus and a decline in its performance when
D. pigrum is present in the polymicrobial consortia.
3.4. Bioﬁlm resistance proﬁles
The bioﬁlms in the required threshold concentration were exposed
to increasing 2-fold concentrations, ranging from 2 to 1024 mg/L, of
nine antibiotics. The MICs, obtained from planktonic populations, and
the MBECs obtained for bioﬁlm consortia are summarized on Table S1.
Results obtained for mixed-species populations were compared to data
obtained from single-species cultures, determined in a previous report
of Lopes et al. (Lopes et al., 2014), where an increase in antibiotic re-
sistance was observed for I. limosus and D. pigrum bioﬁlms. In order to
better visualize the tendency for antibiotic tolerance for those popula-
tions, two heat maps representing the MIC and MBEC data were gen-
erated (Fig. 4a and b, respectively). Bioﬁlm-entrapped bacteria showed
predictable greater tolerance towards antibiotics than planktonic
counterparts, with MBECs (in general≥ 1024 mg/L) higher than MICs,
independently from the oxygen concentration. For planktonic and
bioﬁlm cultures, the activity of most antibiotics was preserved under
environments defective in oxygen. Speciﬁcally, as aminoglycoside up-
take is severely limited in Gram-negative and Gram-positive bacteria
under oxygen-restricted environments (Hancock, 1962; Kogut et al.,
1965; Kohanski et al., 2010), is therefore indicative that oxygen in the
environment (used as the electron acceptor) is the motive force avail-
able to assit the aminoglycoside uptake and maintain sensitive under
anaerobic conditions (it was the case of P. aeruginosa).
Comparing with monospecies planktonic cultures, polymicrobial
populations remained sensitive for most antibiotic agents, with excep-
tion for CLI and RIF, which were ineﬀective in inhibiting those
Fig. 3. Competitive index (CI; black bars) and Relative Increase Ratio (RIR; grey bars) calculated from 6h-old bioﬁlms formed by: (a) P. aeruginosa (PA) and I. limosus (IL); (b) PA and D.
pigrum (DP) and (c) PA, IL and DP. Bioﬁlms were formed under aerobic (AER), microaerophilic (MAER) and anaerobic (ANAER) conditions. Statistical signiﬁcant diﬀerences between CI
and RIR is suggestive of a meaningful competition between the species in the consortia. Competition of species X and species Y in a consortium [CI (X vs Y)] is interpreted as follows:
CI = 0 means similar competition for both X and Y species; CI > 0 means competitive advantage for the species X; CI < 0 means competitive advantage for the species Y. The results are
shown as mean ± SDs. **P < 0.01, ***P < 0.001, ****P < 0.0001, CI vs. RIR, one-way ANOVA with Tukey‘ post-hoc test.
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populations (MBEC > 1024 mg/L). When encased in bioﬁlms, the
unusual species showed high resistance for most antibiotics, which
endured when these species were co-cultured with P. aeruginosa, in-
dependently of the oxygen condition.
3.5. Eﬀect of antibiotics in reducing bioﬁlm cells
Since MBECs were generally high, it was interesting to address how
increasing antibiotic concentrations (at 2, 128 and 1024 mg/L) could
aﬀect the viability of bacterial populations within the polymicrobial
bioﬁlms (Fig. 5). For this, the percentage reduction in total bioﬁlm-cells
was estimated by counting bacteria on TSA after exposing bioﬁlms to
antibiotics and the results compared from those of un-treated bioﬁlms.
Overall, bioﬁlm-cells declined gradually with increasing doses of anti-
biotics, with the highest concentrations leading to the highest reduc-
tions. A clear loss of activity for many antibiotics under low-oxygen
atmospheres was also observed, with no visible cell reductions. This
was particularly true for P. aeruginosa/I. limosus dual-species bioﬁlms,
which showed higher antibiotic resistance under ANAER conditions,
with bioﬁlm-cell reduction percentages not exceeding 10% (achieved
for GEN). Bioﬁlms encompassing D. pigrum were more sensitive than
the previous ones, being markedly noticeable for the consortia invol-
ving the three-species, where antibiotics could achieve great bacterial
reductions within the bioﬁlms and even with ﬂuoroquinolones (LVF
and CIP) leading to the complete eradication for MAER and ANAER
environments.
3.6. Microbial composition of polymicrobial bioﬁlms after antibiotic
treatment
The relative populations proportions of the polymicrobial bioﬁlms
after antibiotic exposure was monitored by culture (Fig. 6). After the
antibiotic treatment, substantial changes in the composition of the
polymicrobial communities occurred compared with non-treated bio-
ﬁlms (i.e. bioﬁlms pre-exposed to antibiotics), with ﬂuctuations de-
pending on the type and on the concentration of the antibiotic and even
on the oxygen conditions. P. aeruginosa/I. limosus dual-species bioﬁlms
were still predominately governed by the CF-classical species, particu-
larly under AER conditions (Fig. 6a). However, I. limosus populations
started to occupy a signiﬁcant proportion, together with P. aeruginosa,
for environments of low oxygen tension (MAER and ANAER). Similarly,
P. aeruginosa prevailed within the P. aeruginosa/D. pigrum dual-species
consortia (Fig. 6b), persisting alone for many cases. For a vast number
of situations, D. pigrum was able to persist and inhabit nearly half part
of the whole consortia, together with P. aeruginosa. Changes in the
microbial composition of three-species bioﬁlms showed to be quite
complex and variable compared with dual-species consortia (Fig. 6c). A
clear dominance of the three-species consortia was typically obtained
for D. pigrum and/or P. aeruginosa, whilst I. limosus populations rapidly
declining.
4. Discussion
The recent explosion of large-scale studies has signiﬁcantly en-
hanced our appreciation on the true complexity and diversity of the CF
multispecies communities. Indeed, the airways and lungs of CF patients
are often heterogeneous systems enclosing gradients of antibiotics,
nutrients, and oxygen (Yang et al., 2011), which have been documented
as signiﬁcant factors driving to the diversiﬁcation at the community
level (Cuthbertson et al., 2016; Goddard et al., 2012; Lee et al., 2014;
Quinn et al., 2016; Rogers et al., 2015; van der Gast et al., 2014; van der
Gast et al., 2011; Zhao et al., 2012).
Our ﬁndings demonstrated that CF polymicrobial communities were
not static populations, with bioﬁlm dynamics evolving in response to
Fig. 4. Antimicrobial tolerance of polymicrobial planktonic (a) and bioﬁlm cultures (b) formed by P. aeruginosa (PA), I. limosus (IL) and D. pigrum (DP) grown for 6 h, under aerobic (AER),
microaerophilic (MAER) and anaerobic (ANAER) conditions. The vertical scale bars represent the range values for MICs (in (a)) and MBECs (in (b),) expressed as mg/L. Legend for
antibiotics: TOB = tobramycin; GEN = gentamicin; LVF = levoﬂoxacin; CIP = ciproﬂoxacin; CLI = clindamycin; CTX = cefotaxime; CAM= chloramphenicol; RIF = rifampicin;
ATM= aztreonam. Data from single-species populations were retrieved from an earlier publication (Lopes et al., 2014). The heatmaps were created by using Seaborn, a Python
visualization library.
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environments with distinct oxygen availabilities and to antibiotic
therapy. Minimal ﬂuctuations were detected before antibiotic exposure,
particularly in terms of bioﬁlm composition. In fact, I. limosus and D.
pigrum were proﬁcient to establish bioﬁlms together with the CF em-
blematic pathogen P. aeruginosa under AER, MAER and ANAER en-
vironments with slight variations in biomass and metabolic activity.
Earlier studies (Lopes et al., 2014) have shown that both unusual spe-
cies were able to develop single-species bioﬁlms under these oxygen
environments, even showing resistance to multiple antibiotics under
those conditions. Several reasons were pointed out to substantiate the
underlying antibiotic resistance for both species, which was particularly
attributed to the mucoid physiology of I. limosus and to the high bio-
mass achieved for D. pigrum bioﬁlms, associated to the dense extra-
cellular polymeric matrix.
It is important to note that co-infections with equal ratios of P.
aeruginosa and the unusual organisms selected may never occur in a CF
lung, but it is possible that all strains might reside in the airways of
patients for identical lengths in time. Strains of P. aeruginosa, I. limosus
and D. pigrum were recovered from CF exacerbations from one geo-
graphical region over a period of just 2 months, which suggests that
they may encounter each other in their natural microhabitat (Bittar
et al., 2008), eventually not as a stable but as a transient community
consequently derived from shifts within the natural environment
(Conrad et al., 2013). While applying PNA-FISH assay to discriminate in
situ the bacterial populations within the bioﬁlms, culture results were
corroborated by microscopy. An exception was observed for P. aerugi-
nosa/I. limosus dual bioﬁlms, where the sparse distribution of I. limosus
indicated a lower prevalence in the consortium. Only an ex situ
quantitative monitoring of bacterial populations should better clarify
this issue. Polymicrobial bioﬁlms were minimally challenged by vari-
able oxygen conditions. Whilst dual-species bioﬁlms (in particular P.
aeruginosa and D. pigrum) presented similar relative proportions for
both populations, the three-species bioﬁlms were dominated by P.
aeruginosa, with D. pigrum also presenting a great extension together
with the CF-traditional species. PNA-FISH and culture assays, com-
plemented with CI and RIR data seems to indicate that D. pigrum/I.
limosus and D. pigrum/P. aeruginosa interplay was likely negative, with
D. pigrum taking competitive advantage against the other species, thus
eventually suggesting competition for the same niche or for nutrients
(Hibbing et al., 2010).
If bioﬁlm dynamics was minimally disturbed with oxygen condi-
tions, treatment with antibiotics had huge impact on multispecies di-
versiﬁcation. First, bioﬁlms demonstrated high resistance towards most
antibiotics compared with respective planktonic cells, which is con-
sistent with the commonly accepted notion that bioﬁlm-grown bacteria
display enhanced resistance to antibiotics, compared to their planktonic
counterparts (Costerton et al., 1999; Hoiby et al., 2010; Lopes et al.,
2012; Mah and O'Toole, 2001). This work, thus, supports that the an-
tibiotic resistance previously demonstrated for I. limosus and D. pigrum
(Lopes et al., 2014) endured even in co-culture with P. aeruginosa, thus
strongly emphasizing the impact that those species may have on CF
antibiotic treatment and pathogenesis. Second, even presenting higher
MBECs, the antibiotics could lead to signiﬁcant reductions in the via-
bility of bacterial populations within the polymicrobial bioﬁlms. The
decline in the cell viability was less noticed for treatments challenged
under ANAER conditions, with a great number of antibiotics losing
Fig. 5. Average percentage reductions in total cultivable cells within polymicrobial bioﬁlms formed by P. aeruginosa (PA), I. limosus (IL) and D. pigrum (DP) after exposure to increasing
doses (2, 128 and 1024 mg/L) of antibiotics under aerobic (AER), microaerophilic (MAER) and anaerobic (ANAER) environments. The means for three independent assays are illustrated.
Legend for antibiotics: TOB = tobramycin; GEN = gentamicin; LVF = levoﬂoxacin; CIP = ciproﬂoxacin; CLI = clindamycin; CTX = cefotaxime; CAM= chloramphenicol;
RIF = rifampicin; ATM= aztreonam.
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their eﬀectiveness under oxygen-limited environments. Third, the
composition of polymicrobial bioﬁlms was dramatically challenged by
antibiotic therapy, with ﬂuctuations depending on the type and con-
centration of the antibiotic applied and on the oxygen environment. But
whatever the antibiotic and concentration applied, it tends to select for
P. aeruginosa rather than for the unusual species. Changes were in
general mainly reﬂected on the relative proportions of I. limosus and/or
D. pigrum, with P. aeruginosa as the eminent organism for most cases. In
turn, changes on bioﬁlms composition instigated by antibiotic therapy
could shape the overall function of the polymicrobial consortia. As an
example, P. aeruginosa/I. limosus dual-species consortia were equally
distributed within the bioﬁlm (as showed by culture), mainly under
ANAER conditions. The demonstrated endurance of I. limosus popula-
tions may indicate that this species was potentially the organism that
conferred resistance to the overall bioﬁlm when challenged under low
oxygen tensions (observed by bacterial killing assays). We therefore
suggest that the enhanced sensitiveness of the three-species consortia
can be related with the clear decline in the I. limosus population size,
with the overall consortia being dominated by P. aeruginosa and D. pi-
grum. This remarks the competition between both unusual species, with
D. pigrum likely disturbing the numbers of the organism that originally
had conferred resistance to the dual-bioﬁlm (mainly under depleted
oxygen conditions) and leading to more susceptible mixed-species
bioﬁlms for a great number of antibiotics, as demonstrated by killing
kinetics assays. Taken together, these results can open novel ways for
CF treatment, by disturbing one factor that regulates the microbial
community (in terms of stability, function and/or antibiotic-resistance)
to facilitate subsequent control of the overall community by antibiotics.
Aware that rather than a single process, a myriad of variants is re-
sponsible for impacting the dynamics of polymicrobial communities in
CF natural settings, leading to diﬀerent scenarios seen in vivo, we were
able to reach a model representing how oxygen environments and an-
tibiotic therapy aﬀect the composition of polymicrobial bioﬁlms in CF
airways (Fig. 7). For this, we focused our model in the three-species
consortia due to their higher complexity comparable with dual-species
bioﬁlms. Prior to antibiotic exposure (Fig. 7a), minor ﬂuctuations occur
across oxygen gradients, with the three-species consortia being domi-
nated by P. aeruginosa (red cells) and D. pigrum (blue) and with I. li-
mosus (green) as the lowest representative population. When bioﬁlms
are exposed to antibiotics commonly used to treat P. aeruginosa infec-
tions in CF (Doring et al., 2012), diversiﬁcation among bioﬁlms is
evident (Fig. 7b), with variable ﬂuctuations occurring in the relative
proportions of the resident species depending on the antibiotic and on
the oxygen conditions.
Fig. 6. Relative bacterial proportions, in average, of P. aeruginosa (PA; red), I. limosus (IL; green) and D. pigrum (DP; blue) cells within polymicrobial bioﬁlms formed by PA and IL (a), PA
and DP (b) and PA, IL and DP (c) before and after exposure to increasing doses (2, 128 and 1024 mg/L) of antibiotics under aerobic (AER), microaerophilic (MAER) and anaerobic
(ANAER) environments. Legend for antibiotics: TOB = tobramycin; GEN = gentamicin; LVF = levoﬂoxacin; CIP = ciproﬂoxacin; CLI = clindamycin; CTX = cefotaxime;
CAM= chloramphenicol; RIF = rifampicin; ATM= aztreonam. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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We are aware that this bioﬁlm model embraces a few limitations
(e.g. it is an in vitro model, based on culture experiments com-
plemented with PNA-FISH; it embodies a mixture of three species rather
than the full diversity and abundance of microbes in CF and hence
dismisses other species with potential huge impact for CF infection).
Nonetheless, it reﬂects how spatially heterogeneous and distributed are
CF communities within the site of infection, likely aﬀecting the viru-
lence of the encased pathogens and being a great predictor of disease
progression and outcome (Stacy et al., 2016). It is therefore plausible
that discerning the mechanisms that govern CF sociomicrobiology will
impair, for instance, that treatment regimens often applied to speciﬁc
populations may be ineﬀective against infections occurring in particular
regions or microenvironments of the lung/airways. Additionally, it may
lead to the development of rationales for the selection of suitable and
personalized therapeutic strategies (targeting microbiomes unique to
each individual), hence increasing antibiotic therapy and reducing so-
cioeconomic repercussion often associated to inadequate treatments.
5. Conclusion
This study expanded the understanding about how the dynamics of
microbial communities involving CF classical and unusual organisms is
collectively inﬂuenced by perturbations often common in the CF nat-
ural environments. In fact, our results led to conclude that chemical
stress is more “aggressive” than environmental stress in modulating the
dynamics of CF polymicrobial communities. While the beneﬁts of an-
tibiotic therapy are indisputable, antibiotics may exert dramatic ﬂuc-
tuations on bioﬁlms, thereby shaping resident species composition and
aﬀecting overall function of the consortia. In parallel, this study high-
lights that the presence of unusual species in the CF airways commu-
nities should not be disregarded, since they are able to mediate social
interactions, aﬀecting the whole community and ultimately modifying
the clinical course of the disease. As such, a more deep appreciation of
the ecological and evolutionary nature that shape the airways com-
munities as well as their eﬀects on lung will be certainly useful for the
optimal use of current therapies and the development of newer break-
throughs on CF antibiotic therapy.
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